This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
The history of Creutzfeldt-Jakob disease (CJD) begins with the independent observations of two German neuropathologists in the early 20th century. Hans Gerhard Creutzfeldt first reported, in 1920, the case of a 23-year-old woman with rapidly progressive dementia, myoclonus and extrapyramidal symptoms. The following year, in 1921, Alfons Maria Jakob published a series of five patient cases with a similar clinical picture, and the name 'Creutzfeldt-Jakob disease', after these two physicians, became established. Initially it was unclear even which category the disease belonged to, and for decades it was known only as a rare neurodegenerative disease of unknown cause.
Research on kuru, which was epidemic among the Fore people of Papua New Guinea during the 1950s–60s, became a turning point in understanding CJD. D. Carleton Gajdusek demonstrated that kuru is transmitted by an infectious agent and received the 1976 Nobel Prize in Physiology or Medicine for this work. Then in 1982, Stanley Prusiner proposed that the cause of this group of diseases, including CJD, is a protein particle that is infectious on its own without nucleic acid, namely the prion. This revolutionary concept initially met fierce scientific opposition, but extensive experimental evidence subsequently accumulated, and Prusiner was the sole recipient of the 1997 Nobel Prize in Physiology or Medicine.
In 1996, a new form of CJD was reported in the United Kingdom. Unlike classic sporadic CJD, this disease arose at a much younger age (mean 29 years) and differed in clinical course and neuropathologic findings; it was named variant CJD (vCJD). Epidemiological and experimental studies showed that vCJD is associated with eating beef contaminated with the agent of bovine spongiform encephalopathy (BSE, mad cow disease), which heightened food safety awareness worldwide and brought major changes to public health policy.
The cause of CJD is the prion. A prion is an infectious particle composed only of protein, containing no nucleic acid (DNA or RNA), and is a pathogen fundamentally different from conventional viruses and bacteria. The cellular prion protein normally present on the surface of nerve cells (PrPC) is converted into an abnormal structure, and the resulting PrPSc is pathogenic. PrPC has a mainly alpha-helical structure, whereas PrPSc has increased beta-sheet structure, is highly prone to aggregation, is resistant to proteinase K and is cytotoxic.
CJD is broadly classified into three forms according to cause. Sporadic CJD (sCJD) is the most common form, accounting for about 85% of the total; it is presumed to result from spontaneous structural conversion of PrPC to PrPSc without an apparent cause, or from somatic mutation, but the exact mechanism has not yet been fully elucidated. Genetic CJD (fCJD) accounts for about 10–15% of the total and is caused by germline mutations in the PRNP gene. Acquired CJD includes iatrogenic CJD (iCJD) and variant CJD (vCJD) and accounts for less than about 1% of the total. Iatrogenic CJD is transmitted through contaminated surgical instruments, dura mater grafts, growth hormone injections and similar routes.
The PRNP gene is located on the short arm of chromosome 20 (20p13) and encodes the prion protein (PrP). This gene, consisting of a single exon, produces a protein of 253 amino acids and is normally widely expressed in nerve cells, glial cells and others. PRNP mutations associated with genetic CJD (fCJD) include E200K (frequent in Europe and in Libyan-origin Jews in Israel), V210I and D178N (shared with FFI), and insertion mutations in the octapeptide repeat sequence have also been reported.
The methionine (M)/valine (V) polymorphism at PRNP codon 129 is closely related to CJD susceptibility. Met/Met (MM) homozygotes have a markedly higher risk of sporadic CJD and variant CJD. In fact, almost all confirmed vCJD patients were codon 129 MM homozygotes, which is interpreted as the polymorphism affecting the efficiency of structural conversion of the prion protein. The Val/Val (VV) or Met/Val (MV) phenotypes show relatively low susceptibility.
Genetic CJD shows an autosomal dominant inheritance pattern. Penetrance differs by mutation type but is mostly high, and the age of onset varies widely depending on the mutation type and the codon 129 polymorphism. When there is a family history, genetic counseling and PRNP gene testing may be considered, but in the absence of a cure, predictive genetic testing requires ethical consideration.
The annual incidence of CJD worldwide is estimated at about 1–2 per million population. This figure varies somewhat by country and region but generally remains at a constant level. The male-to-female ratio is almost equal, and there is no significant difference between races. Several thousand new cases are estimated to occur worldwide each year.
Sporadic CJD accounts for 85% of all CJD, with a mean age of onset of 60–65 years. Genetic CJD shows a relatively high incidence in certain populations (e.g., frequent E200K mutation in Libyan-origin Israeli Jews). Variant CJD has occurred mainly in the United Kingdom since 1996; cumulative cases worldwide number over about 230, many of them reported in the United Kingdom and France. Iatrogenic CJD has been reported in several hundred cases worldwide, centered on patients who received contaminated pituitary-derived growth hormone treatment.
In the Republic of Korea, CJD is designated as a Class 2 legally notifiable infectious disease, and reporting is mandatory. Since 2010, around 30–50 CJD cases have been reported in Korea each year, most of them sporadic CJD. One case of variant CJD was reported in Korea in 2011. The Korea Disease Control and Prevention Agency (KDCA) operates a CJD surveillance system and conducts reporting, epidemiological investigation and pathologic confirmation of suspected cases.
The core pathogenesis of CJD is the process by which the normal cellular prion protein PrPC is structurally converted into the abnormal isoform PrPSc. PrPC contains mainly alpha-helical structure (about 42%) and is sensitive to proteases, whereas PrPSc has increased beta-sheet structure (about 43%) and is resistant to proteinase K. PrPSc binds normal PrPC and acts as a template that promotes chain-reaction structural conversion, so that pathogenic prions are amplified exponentially.
Accumulation of PrPSc induces nerve cell death through several pathways. Mitochondrial dysfunction, endoplasmic reticulum stress (ER stress), abnormalities of the autophagy pathway and excessive activation of glial cells are involved in combination. As a result, neuronal loss, reactive astrogliosis and spongiform vacuole formation in the brain parenchyma (spongiform change) appear, with widespread involvement of the cerebral cortex, basal ganglia, cerebellum and other regions. In the brain, PrPSc may also form amyloid plaques.
In acquired CJD, externally introduced PrPSc is presumed to be absorbed and amplified mainly through the lymphatic system of the gastrointestinal tract and then spread to the brain through peripheral nerves and the autonomic nervous system. The incubation period of prions can range from several years to several decades, during which neural damage progresses slowly until the stage of clinical symptom onset is reached.
The early symptoms of CJD differ somewhat by form, but in sporadic CJD rapidly progressive cognitive decline (rapid dementia) is prominent. Within weeks to months, patients experience memory decline, impaired judgment, confusion and visuospatial perception abnormalities, and in some, psychiatric symptoms such as anxiety, depression and behavioral changes come first. In variant CJD, psychiatric symptoms (depression, anxiety, abnormal sensations, etc.) often persist for several months in the early stage before neurologic symptoms appear.
As the disease progresses, cerebellar ataxia, myoclonus, extrapyramidal signs, pyramidal signs, visual disturbances and others are added. Myoclonus in particular is a characteristic finding of CJD: involuntary muscle contractions provoked by sudden stimuli (sound, light, touch) or occurring spontaneously. Epileptic seizures may also occur.
In the terminal stage, akinetic mutism appears, and the patient falls into a state of almost no voluntary movement or verbal expression. Complications such as aspiration pneumonia due to dysphagia, pressure ulcers and urinary tract infections follow, eventually leading to death. The mean survival of sporadic CJD is about 4–6 months after onset, and about 90% die within 1 year.
On neurologic examination, myoclonus is the most characteristic sign. In addition, cerebellar signs (gait ataxia, limb incoordination, nystagmus), pyramidal signs (hyperreflexia, Babinski reflex), extrapyramidal signs (rigidity, bradykinesia) and cortical visual disturbance (cortical blindness) are observed. In the terminal stage, rigidity, flexed posture and mutism predominate.
In the Heidelberg sign (Heidenhain variant), visual symptoms are prominent from the beginning, with cortical blindness or visual hallucinations. In some patients, there is also a cerebellar type, in which cerebellar ataxia is the main early symptom, and a thalamic type, mainly involving the hypothalamus and thalamus. Autonomic nervous system abnormalities (orthostatic hypotension, abnormal sweating) may also be observed.
On electroencephalography (EEG), periodic sharp wave complexes (PSWC) are observed in about 60–70% of sporadic CJD. They appear in a periodic pattern of 1–2Hz and have high diagnostic value. However, because PSWC appear mainly in the middle to late stages of CJD, they may be negative early on, and they rarely appear in variant CJD.
On cerebrospinal fluid (CSF) testing, a positive 14-3-3 protein has long been used as a supportive criterion for the diagnosis of CJD. The 14-3-3 protein is released when nerve cells are damaged and shows a sensitivity of about 85–90% and a specificity of about 90%. However, false positives can occur in other acute neurologic diseases (stroke, encephalitis, metabolic encephalopathy, etc.), so it must be interpreted in the clinical context. CSF total tau protein also shows high diagnostic sensitivity, and CJD is particularly likely when total tau is 1,300 pg/mL or higher.
The real-time quaking-induced conversion (RT-QuIC) test is an ultrasensitive method that amplifies and detects trace amounts of PrPSc in CSF or nasal mucosal samples (nasal brushing), showing a sensitivity of about 92–97% and a specificity of about 99% or higher. It is currently regarded as the most reliable biochemical test for the diagnosis of CJD and is included in the CJD diagnostic guidelines of several countries, including Korea.
On brain MRI diffusion-weighted imaging (DWI), ribbon-like restricted diffusion of the cerebral cortex (cortical ribboning) and hyperintense lesions of the basal ganglia (caudate nucleus, putamen) are characteristic findings of CJD. These findings may appear before neuronal loss and are useful for early diagnosis, with a reported sensitivity of about 90% and specificity of about 95%. In variant CJD, bilateral symmetric hyperintensity of the thalamus (especially the pulvinar) (pulvinar sign) is characteristic.
A definite diagnosis of CJD is made from characteristic pathologic findings (spongiform degeneration, positive PrPSc immunohistochemistry, etc.) obtained by brain tissue biopsy or autopsy. In clinical practice, the WHO or European CJD surveillance criteria are applied to classify cases as definite, probable or possible. Probable CJD is diagnosed when rapidly progressive dementia is accompanied by at least one of PSWC on EEG, positive CSF 14-3-3, characteristic MRI DWI findings or positive RT-QuIC.
Major diseases to differentiate from CJD include autoimmune encephalitis (anti-NMDAR encephalitis, LGI1 encephalitis, etc.), metabolic encephalopathy (hepatic, uremic), central nervous system vasculitis, Alzheimer's disease (rapidly progressive form), dementia with Lewy bodies, brain tumors and paraneoplastic syndromes. Because autoimmune encephalitis is treatable, active differentiation including antineuronal antibody testing is important.
Pathologic findings in brain tissue are characterized by spongiform change, neuronal loss and reactive astrogliosis. Immunohistochemical staining for PrPSc, Western blot and electron microscopy are used for diagnosis. Autopsy is the most certain means of confirming the diagnosis, and because CJD is a legally notifiable infectious disease with mandatory reporting, proper handling procedures must be followed after death.
There is currently no curative treatment for CJD. Various drugs, including pentosan polysulphate, quinacrine, amphotericin B and doxycycline, have been tried in efforts to develop therapies that block structural conversion of the prion protein or remove PrPSc, but no significant effect has been confirmed in clinical trials. Recently, new approaches such as antisense oligonucleotides (ASO) that suppress prion protein expression are in preclinical and early clinical research.
Palliative care is the center of treatment. Clonazepam or valproate is used for myoclonus, and anticonvulsants are given for epileptic seizures. Symptomatic treatment for pain, anxiety and insomnia is provided, and if dysphagia is severe, nasogastric tube or percutaneous gastrostomy feeding is considered. Supportive therapy such as pressure ulcer prevention, management of urinary tract infections and prevention of aspiration pneumonia is also important.
Because the brain, cerebrospinal fluid and ocular tissue of patients with CJD are infectious, standard infection prevention guidelines must be strictly followed during procedures. Because prions are resistant to conventional sterilization methods (boiling, ethanol, formalin), special methods such as autoclaving (at 134°C or higher) or sodium hydroxide treatment are applied to contaminated medical devices.
As far as is currently known, CJD is an incurable fatal disease. About 90% of patients with sporadic CJD die within 1 year of onset, and the median survival is about 4–6 months. Survival in genetic CJD varies from several months to several years depending on the type of mutation. The mean survival of variant CJD is about 13 months, somewhat longer than the sporadic form, but all patients eventually die.
Survival tends to be somewhat longer with a younger age at onset, in PRNP codon 129 MV heterozygotes and depending on the specific prion strain type. In addition, when cerebellar signs are the main symptom at onset, survival may be longer than when acute cognitive decline is the main symptom.
After diagnosis, it is important to establish a comprehensive palliative care plan for the patient and family early. Completion of an advance directive on life-sustaining treatment, referral to hospice care and family support services are needed. Along with psychological and emotional support, linking to social welfare resources to reduce the caregiving burden on family members should also be considered.
To prevent iatrogenic CJD, countries have replaced the use of pituitary-derived growth hormone with recombinant growth hormone, and strict donor screening and the use of substitute materials are also recommended for dura mater grafts. Neurosurgical instruments are processed with the special sterilization methods mentioned above. Blood and organ donation from patients with CJD or high-risk groups is prohibited.
To prevent variant CJD, international regulations have been implemented that completely prohibit the food use of products from BSE-infected cattle, especially specified risk materials (SRM) such as the brain and spinal cord. Management of BSE-affected countries is also applied to imported beef, and Korea likewise strictly enforces the relevant quarantine standards.
Because CJD is designated in Korea as a Class 2 legally notifiable infectious disease, suspected or confirmed cases must be reported to the local public health center. The Korea Disease Control and Prevention Agency (KDCA) monitors occurrence trends through CJD surveillance and conducts epidemiological investigations and provides testing support for suspected cases. Confirmation by autopsy after death and compliance with guidelines for proper handling of the body are also part of infection prevention.